Related Experiment Video
Updated: Jun 21, 2026

Nucleocapsid Annealing-Mediated Electrophoresis (NAME) Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors
Published on: January 19, 2015
The nucleoside analogue D-carba T blocks HIV-1 reverse transcription
Paul L Boyer1, B Christie Vu, Zandrea Ambrose
1HIV Drug Resistance Program, NCI-Frederick, Frederick, Maryland 21702, USA.
Abstract:
A major pathway for HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs) involves reverse transcriptase (RT) mutations that enhance ATP-dependent pyrophosphorolysis, which excises NRTIs from the end of viral DNA. We analyzed novel NRTIs for their ability to inhibit DNA synthesis of excision-proficient HIV-1 RT mutants. D-carba T is a carbocyclic nucleoside that has a 3' hydroxyl on the pseudosugar. The 3' hydroxyl group allows RT to incorporate additional dNTPs, which should protect D-carba TMP from excision. D-carba T can be converted to the triphosphate form by host cell kinases with moderate efficiency. D-carba T-TP is efficiently incorporated by HIV-1 RT; however, the next dNTP is added slowly to a D-carba TMP at the primer terminus. D-carba T effectively inhibits viral vectors that replicate using NRTI-resistant HIV-1 RTs, and there is no obvious toxicity in cultured cells. NRTIs based on the carbocyclic pseudosugar may offer an effective approach for the treatment of HIV-1 infections.
Insights
Novel nucleoside reverse transcriptase inhibitors (NRTIs) show promise against drug-resistant HIV-1. D-carba T, a carbocyclic nucleoside, effectively inhibits viral replication with no observed toxicity in cell cultures.
Area of Science:
- Biochemistry
- Virology
- Medicinal Chemistry
Background:
- HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs) is a significant clinical challenge.
- This resistance often arises from mutations in reverse transcriptase (RT) that promote NRTI excision via pyrophosphorolysis.
- Developing NRTIs that overcome these resistance mechanisms is crucial for effective HIV-1 treatment.
Purpose of the Study:
- To evaluate novel nucleoside analogs, specifically D-carba T, for their efficacy against HIV-1 RT mutants exhibiting excision proficiency.
- To investigate the mechanism of action and potential therapeutic value of D-carba T in the context of NRTI resistance.
Main Methods:
- Synthesis and characterization of D-carba T, a carbocyclic nucleoside analog.
- Assessment of D-carba T's conversion to its active triphosphate form (D-carba T-TP) by host cell kinases.
- Evaluation of HIV-1 RT's incorporation of D-carba T-TP and subsequent nucleotide addition kinetics.
- Testing the antiviral activity of D-carba T against viral vectors utilizing NRTI-resistant HIV-1 RTs.
- In vitro toxicity assessments in cultured cells.
Main Results:
- D-carba T is efficiently converted to D-carba T-TP by host kinases.
- HIV-1 RT readily incorporates D-carba T-TP, but subsequent dNTP addition to the primer terminus is significantly slowed.
- D-carba T demonstrated effective inhibition of viral vectors harboring NRTI-resistant HIV-1 RTs.
- No significant toxicity was observed in cultured cells treated with D-carba T.
Conclusions:
- Carbocyclic nucleoside analogs like D-carba T represent a promising strategy for combating NRTI-resistant HIV-1.
- The unique structure of D-carba T confers resistance to pyrophosphorolytic excision, a key resistance mechanism.
- Further development of NRTIs based on the carbocyclic pseudosugar scaffold holds potential for improved HIV-1 treatment regimens.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Viruses with RNA Genomes
Inhibitors of Viral Protein Synthesis
Inhibitors of Virion Maturation and Assembly
Retrovirus Life Cycles
Retroviruses

